| Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study AP Kater, JQ Wu, T Kipps, B Eichhorst, P Hillmen, J D’rozario, S Assouline, ... Journal of Clinical Oncology 38 (34), 4042, 2020 | 191 | 2020 |
| Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment I de Weerdt, T Hofland, R de Boer, JA Dobber, J Dubois, ... Blood advances 3 (17), 2642-2652, 2019 | 101 | 2019 |
| Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL MV Haselager, K Kielbassa, J Ter Burg, DJC Bax, SM Fernandes, J Borst, ... Blood, The Journal of the American Society of Hematology 136 (25), 2918-2926, 2020 | 83 | 2020 |
| Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia AC Leeksma, J Taylor, B Wu, JR Gardner, J He, M Nahas, M Gonen, ... Leukemia 33 (2), 390-402, 2019 | 64 | 2019 |
| Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary … AP Kater, MD Levin, J Dubois, S Kersting, L Enggaard, GJ Veldhuis, ... The Lancet Oncology 23 (6), 818-828, 2022 | 31 | 2022 |
| Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia CU Niemann, MD Levin, J Dubois, S Kersting, L Enggaard, GJ Veldhuis, ... Blood, The Journal of the American Society of Hematology 137 (8), 1117-1120, 2021 | 30 | 2021 |
| Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax+ obinutuzumab in CLL AP Kater, S Kersting, Y van Norden, J Dubois, JA Dobber, CH Mellink, ... Blood advances 2 (24), 3566-3571, 2018 | 25 | 2018 |
| High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations M Fürstenau, YJ Thus, S Robrecht, CHM Mellink, ... Blood 142 (5), 446-459, 2023 | 19 | 2023 |
| Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of … S Kersting, J Dubois, K Nasserinejad, JA Dobber, C Mellink, ... The Lancet Haematology 9 (3), e190-e199, 2022 | 19 | 2022 |
| Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)-15-month safety, response and MRD evaluation: third interim analysis from … CU Niemann, J Dubois, S Kersting, L Enggaard, GJ Veldhuis, R Mous, ... Blood 134, 4292, 2019 | 14 | 2019 |
| JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL MV Haselager, R Thijssen, D Bax, D Both, F De Boer, S Mackay, J Dubois, ... Molecular oncology 17 (6), 1112-1128, 2023 | 10 | 2023 |
| First evidence of restoration of T and NK cell compartment after venetoclax treatment I de Weerdt, T Hofland, J Dobber, J Dubois, E Eldering, M Mobasher, ... Blood 132, 1860, 2018 | 9 | 2018 |
| Identification of methylguanine methyltransferase polymorphisms as genetic markers of individual susceptibility to therapy-related myeloid neoplasms J Dubois, G Etienne, A Laroche-Clary, A Lascaux, A Bidet, E Lippert, ... European Journal of Cancer 50 (2), 418-424, 2014 | 9 | 2014 |
| Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells JAC van Bruggen, GJW van der Windt, M Hoogendoorn, J Dubois, ... Blood advances 6 (14), 4185-4195, 2022 | 8 | 2022 |
| Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL L Van Der Straten, CAM Stege, S Kersting, K Nasserinejad, J Dubois, ... Blood 142 (13), 1131-1142, 2023 | 6 | 2023 |
| Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation K Kielbassa, MV Haselager, DJC Bax, BF van Driel, J Dubois, MD Levin, ... Leukemia 37 (6), 1268-1276, 2023 | 6 | 2023 |
| Assessment of the clonal dynamics of acquired mutations in patients (Pts) with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) treated in the randomized phase 3 … JF Seymour, JQ Wu, R Popovic, B Eichhorst, P Hillmen, TJ Kipps, ... Blood 138, 1548, 2021 | 5 | 2021 |
| Ibrutinib treatment in CLL interrupts CD40 signaling capacity and sensitizes CLL cells to venetoclax K Kielbassa, M Haselager, D Bax, J Dubois, MD Levin, PE Westerweel, ... Blood 138, 1545, 2021 | 4 | 2021 |
| Time-Limited venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who have undetectable MRD-Primary analysis from the … CU Niemann, J Dubois, C Brieghel, S Kersting, L Enggaard, GJ Veldhuis, ... Blood 138, 69, 2021 | 4 | 2021 |
| Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110 PJ Hengeveld, YE Ertem, JMN Dubois, CHM Mellink, ... Leukemia 36 (7), 1935-1938, 2022 | 3 | 2022 |
